Answers are grounded in this paper and cite their sources.
Importance After the US Food and Drug Administration approval of zopapogene imadenovec-drba and its recommendation as the first-line treatment for recurrent respiratory papillomatosis (RRP) in the RRP Foundation Position Statement, standard-of-care treatment for adults with RRP is changing. Practical questions arise with real-world implementation for any new treatment previously studied only in clinical trials. This Narrative Review aims to provide additional information beyond what is published in clinical trial reports to help otolaryngologists and medical oncologists consider how to implement zopapogene imadenovec-drba in their RRP practices. Observations In the pivotal phase 1/2 nonrandomized clinical trial, 51% of patients (18 of 35) achieved a complete response, defined as no clinically indicated surgical procedure received in the 12 months after treatment. This review provides further key information underlying the rationale behind the zopapogene imadenovec-drba pivotal trial design and considerations for clinical implementation and in specific populations. Conclusions and Relevance Zopapogene imadenovec-drba represents a novel immunotherapeutic approach designed to induce targeted durable disease control in adult RRP. This review provides practical guidance on patient selection, treatment administration, and perioperative management to support the clinical integration of nonsurgical management into routine otolaryngology and medical oncology practice.
No takes yet. Share an insight, caveat, or question.
Norberg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: